对侵袭性催乳素瘤进行体细胞突变筛查的证据

IF 31 1区医学 Q1 ENDOCRINOLOGY & METABOLISM

Nature Reviews Endocrinology Pub Date : 2024-06-17 DOI:10.1038/s41574-024-01010-x

Marily Theodoropoulou, Stephan Petersenn, Philippe Chanson, Gerald Raverot

引用次数: 0

摘要

最近关于分泌催乳素的垂体腺瘤（催乳素瘤）的诊断和管理的共识声明引起了人们对分子致病机制的关注。我们认为，对部分病例进行体细胞SF3B1热点变异筛查，可能会对侵袭性肿瘤行为发出警报，并促使对这些具有挑战性的肿瘤进行及时处理和密切随访。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Evidence for somatic mutation screening on aggressive prolactinomas

The recent Consensus Statement on the diagnosis and management of prolactin-secreting pituitary adenomas (prolactinomas) drew attention to molecular pathogenetic mechanisms. We comment that somatic screening for SF3B1 hotspot variants in select cases might alert to aggressive tumour behaviour and prompt the timely management and intense follow up of these challenging tumours.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Nature Reviews Endocrinology 医学-内分泌学与代谢

CiteScore

42.00

自引率

0.70%

发文量

158

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Endocrinology aspires to be the foremost platform for reviews and commentaries catering to the scientific communities it serves. The journal aims to publish articles characterized by authority, accessibility, and clarity, enhanced with easily understandable figures, tables, and other visual aids. The goal is to offer an unparalleled service to authors, referees, and readers, striving to maximize the usefulness and impact of each article. Nature Reviews Endocrinology publishes Research Highlights, Comments, News & Views, Reviews, Consensus Statements, and Perspectives relevant to researchers and clinicians in the fields of endocrinology and metabolism. Its broad scope ensures that the work it publishes reaches the widest possible audience.